Brief: ANI Pharmaceuticals Q2 Adjusted EPS USD 2.21 Vs. IBES Estimate USD 2.05
07/08/2026 11:51
BRIEF-ANI Pharmaceuticals Q2 Adjusted EPS USD 2.21 Vs. IBES Estimate USD 2.05 Aug 07 (Reuters) - ANI Pharmaceuticals Q2 adjusted EBITDA USD 71.6 million.
- Q2 EPS USD 1.05
- Q2 net income USD 24.7 million
- outlook FY adjusted EBITDA USD 285-300 million
- outlook FY revenue USD 1,080-1,140 million vs. IBES estimate USD 1,119 million
- outlook FY adjusted EPS USD 9.19-9.69 vs. IBES estimate USD 9.45
Recent news on ANI Pharmaceuticals
See all newsBrief: Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules
Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
Brief: Ani Pharmaceuticals Appoints Henry Gosebruch To Board Of Directors
U.S. RESEARCH ROUNDUP-Compass Minerals, Duke Energy, Tesla
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary